Page last updated: 2024-09-05

tolvaptan and pituitrin

tolvaptan has been researched along with pituitrin in 61 studies

Compound Research Comparison

Studies
(tolvaptan)
Trials
(tolvaptan)
Recent Studies (post-2010)
(tolvaptan)
Studies
(pituitrin)
Trials
(pituitrin)
Recent Studies (post-2010) (pituitrin)
96717278622,1375942,101

Research

Studies (61)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (24.59)29.6817
2010's32 (52.46)24.3611
2020's14 (22.95)2.80

Authors

AuthorsStudies
Gheorghiade, M; Orlandi, C; Zimmer, CA1
Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC; Orlandi, C; Ouyang, J; Smith, WB; Zimmer, CA1
Greenberg, A; Verbalis, JG1
Gross, P; Quittnat, F1
Kamyar, M; Lemmens-Gruber, R1
Gross, P; Herbrig, K; Palm, C; Pistrosch, F1
Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ1
Bricmont, P; Mallikaarjun, S; Shoaf, SE; Wang, Z1
Aki, S; Furuta, T; Minamikawa, J; Nishi, T; Torisawa, Y1
Hobbs, RE; Tang, WH1
Laczi, F1
Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT; Parissis, J1
Whellan, DJ1
Blair, JE; Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, H; Maggioni, AP; Orlandi, C; Swedberg, K; Traver, B; Udelson, JE; Zannad, F; Zimmer, C1
Gross, P; Herbrig, K; Marczewski, T1
Dhalla, NS; Rehsia, NS1
Reilly, T; Schork, MR1
Singh, M; Slawsky, MT; Valania, G1
Villabona, C1
Hix, J; Sterns, R1
Hori, M1
Fujiki, H; Nivens, E; Pinto, CS; Reif, GA; Wallace, DP; Yamaguchi, T1
Bilsker, M; Hauptman, PJ; Konstam, MA; O'Brien, T; Orlandi, C; Sequeira, R; Thomas, I; Udelson, JE; Zimmer, C1
Akioka, Y; Fujita, T; Hashimoto, M; Hisano, M; Igarashi, T; Iida, A; Iiri, T; Makita, N; Manaka, K; Miura, K; Sekine, T; Takahashi, K; Takubo, N; Ueda, N1
Inomata, T1
de Boer, H; Janssens, PM; Roelofsen, A1
Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F1
Bhatt, DL; Cavender, MA1
Ambrosy, AP; Butler, J; Fonarow, GC; Gheorghiade, M; Konstam, MA; Maggioni, A; Mentz, RJ; Subacius, H; Swedberg, K; Vaduganathan, M; Zannad, F1
Bankir, L; Bouby, N; Ritz, E1
Buehrer, BA; Cassell, MD; Davis, DR; Grobe, JL; Hilzendeger, AM; Ketsawatsomkron, P; Li, H; Littlejohn, NK; Liu, X; Pearson, NA; Pelham, CJ; Siel, RB; Sigmund, CD; Thompson, AP; Weidemann, BJ1
Hew-Butler, T; Hummel, J; Rider, BC; Verbalis, JG1
Al Therwani, S; Bech, JN; Jensen, JM; Mose, FH; Pedersen, EB1
Adams, KF; Lin, TE; Patterson, JH1
Egami, N; Kakigi, A; Takeda, T; Yamasoba, T1
Chen, C; Chen, RP; Huang, XL; Huang, ZM; Lin, HH; Zhang, WY1
Nitta, D1
Izumi, N; Kurosaki, M; Nakanishi, H1
Tesař, V1
Gustafsson, F; Vishram-Nielsen, JK1
De Rechter, S; Janssens, P; Liebau, MC; Mekahli, D; Weydert, C; Wissing, KM1
Torres, VE; van Gastel, MDA1
Garrahy, A; Hannon, AM; Thompson, CJ; Williams, DJ; Zia-Ul-Hussnain, HM1
Jolobe, OMP1
Sterns, RH1
Han, Q; Liu, M; Yang, J1
Mohieldin, AM; Nauli, SM; Ostrom, RS; Pala, R; Sherpa, RT; Wachten, D1
Arima, H; Goto, K; Hirano, T; Ishikawa, SE; Motozawa, T; Mouri, M; Watanabe, R1
B, N; Jayadeep, S; Khan, MF; Pai, K; Varma, M; Vidyasagar, S1
Capasso, G; Cordat, E; Costanzo, V; Guarino, S; Iervolino, A; Jelen, S; La Manna, A; Marzuillo, P; Miraglia Del Giudice, E; Perna, AF; Prosperi, F; Suzumoto, Y; Trepiccione, F; Zacchia, M1
Alukal, JJ; John, S; Thuluvath, PJ1
de Jong-Laird, A; Kabra, M; Lindner, U; Pose-Reino, A; Runkle de la Vega, I1
Doi, T; Fukahara, K; Imamura, T; Kinugawa, K; Yamashita, S; Yokoyama, S; Yoshimura, N1
Kimura, Y; Kusumi, F; Matsumoto, A; Matsuyama, S; Minami, R; Ohana, M; Okano, A; Ozawa, T; Takeda, Y; Ueo, T1
Aihara, M; Fujiki, H; Hattori, K; Isakari, Y; Mizuguchi, H; Nagano, K; Ohmoto, K; Takeshita, Y; Yamada, Y; Yamamoto, M; Yamamura, Y1
Kokubu, N; Kouzu, H; Nagano, N; Noto, T; Osanami, A; Tanno, M1
Cao, X; Chen, T; Fu, K; Guo, D; Hu, H; Liu, H; Ren, Y; Su, L; Wang, P; Yuan, H; Zhang, Y; Zhao, W1
Torres, VE; Zhou, JX1
Bird-Lieberman, G; Bockenhauer, D; Gilbert, RD; Hoogenboom, L; Kumaran, A; Moon, RJ; Singh, J; Soliman, M1
Gärtner, F; Jansen, O; Laudes, M; Reinke, LM; Rohmann, N; Schreiber, S; Schulte, DM; Seoudy, AK1
Baba, K; Horikirizono, H; Igase, M; Kambayashi, S; Kimura, K; Mizuno, T; Okuda, M; Tamura, Y; Yamamoto, H1

Reviews

23 review(s) available for tolvaptan and pituitrin

ArticleYear
Role of vasopressin antagonists in the management of acute decompensated heart failure.
    Current heart failure reports, 2005, Volume: 2, Issue:3

    Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Stroke Volume; Tolvaptan; Treatment Outcome; Vasoconstriction; Vasopressins

2005
Vasopressin receptor antagonists.
    Kidney international, 2006, Volume: 69, Issue:12

    Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins

2006
Vaptans and the treatment of water-retaining disorders.
    Seminars in nephrology, 2006, Volume: 26, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Tolvaptan; Vasopressins; Water

2006
Vasopressin antagonists.
    Cellular and molecular life sciences : CMLS, 2006, Volume: 63, Issue:15

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Binding Sites; Cardiovascular Diseases; Clinical Trials as Topic; Hormone Antagonists; Humans; Indoles; Pyrroles; Pyrrolidines; Tolvaptan; Vasopressins; Water-Electrolyte Imbalance

2006
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    The American journal of medicine, 2006, Volume: 119, Issue:7 Suppl 1

    Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins

2006
Hyponatremia and vasopressin antagonism in congestive heart failure.
    Clinical cardiology, 2007, Volume: 30, Issue:11

    Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins

2007
Vasopressin receptor antagonists in heart failure.
    Recent patents on cardiovascular drug discovery, 2006, Volume: 1, Issue:2

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Receptors, Vasopressin; Tolvaptan; Vasopressins

2006
[Etiology, diagnostics and therapy of hyponatremias].
    Orvosi hetilap, 2008, Jul-20, Volume: 149, Issue:29

    Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain Diseases; Central Nervous System; Chronic Disease; Demeclocycline; Demyelinating Diseases; Diagnosis, Differential; Diuretics; Extracellular Fluid; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lithium Compounds; Morpholines; Osmolar Concentration; Osmosis; Pyrroles; Severity of Illness Index; Sodium; Spiro Compounds; Time Factors; Tolvaptan; Vasopressins

2008
Hyponatremia in heart failure.
    Heart failure reviews, 2009, Volume: 14, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Prognosis; Sodium; Tolvaptan; Treatment Outcome; Vasopressins

2009
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
    Heart failure reviews, 2010, Volume: 15, Issue:1

    Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins

2010
Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:4

    Topics: Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Neurotransmitter Agents; Pyrroles; Tolvaptan; Vasopressins

2010
Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?
    Current heart failure reports, 2011, Volume: 8, Issue:3

    Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hyponatremia; Prognosis; Pyrroles; Tolvaptan; Vasoconstriction; Vasopressins

2011
[Vasopressin receptor antagonists: the vaptans].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57 Suppl 2

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins

2010
Tolvaptan for heart failure patients with volume overload.
    Cardiovascular drugs and therapy, 2011, Volume: 25 Suppl 1

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Edema, Cardiac; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins

2011
[Tolvaptan (vasopressin receptor antagonist)].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Benzazepines; Cardiomyopathy, Dilated; Diuretics; Heart Failure; Humans; Tolvaptan; Vasopressins

2011
Vasopressin: a novel target for the prevention and retardation of kidney disease?
    Nature reviews. Nephrology, 2013, Volume: 9, Issue:4

    Topics: Animals; Benzazepines; Disease Progression; Humans; Hypertension, Renal; Incidence; Prevalence; Renal Insufficiency, Chronic; Tolvaptan; Vasopressins

2013
Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Heart failure clinics, 2014, Volume: 10, Issue:4

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Hyponatremia; Prospective Studies; Tolvaptan; Vasopressins

2014
Management of ascites in cirrhotic patients.
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2017, Volume: 114, Issue:1

    Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Diuretics; Humans; Japan; Liver Cirrhosis; Practice Guidelines as Topic; Receptors, Vasopressin; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Tolvaptan; Vasopressins

2017
Vasopressin and Vasopressin Antagonists in Heart Failure.
    Handbook of experimental pharmacology, 2017, Volume: 243

    Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Glycopeptides; Heart Failure; Hemodynamics; Humans; Hyponatremia; Receptors, Vasopressin; Tolvaptan; Vasopressins

2017
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:3

    Topics: Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Child; Cyclic AMP; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Signal Transduction; Tolvaptan; Vasopressins

2018
Polycystic Kidney Disease and the Vasopressin Pathway.
    Annals of nutrition & metabolism, 2017, Volume: 70 Suppl 1

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins

2017
Hyponatremia in Cirrhosis: An Update.
    The American journal of gastroenterology, 2020, Volume: 115, Issue:11

    Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Albumins; Antidiuretic Hormone Receptor Antagonists; Ascites; Fluid Therapy; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Renin-Angiotensin System; Saline Solution, Hypertonic; Splanchnic Circulation; Tolvaptan; Vasodilation; Vasopressins

2020
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Advances in kidney disease and health, 2023, Volume: 30, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Renal Insufficiency; Tolvaptan; United States; Vasopressins

2023

Trials

9 trial(s) available for tolvaptan and pituitrin

ArticleYear
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    American journal of physiology. Renal physiology, 2006, Volume: 290, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Diuretics; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Placebos; Potassium; Sodium; Tolvaptan; Urination; Vasopressins; Water; Water-Electrolyte Balance

2006
Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
    Journal of clinical pharmacology, 2007, Volume: 47, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzazepines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neurophysins; Protein Precursors; Tablets; Thirst; Tolvaptan; Urination; Vasopressins

2007
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Aged, 80 and over; Benzazepines; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Revascularization; Pacemaker, Artificial; Prospective Studies; Tolvaptan; Vasopressins

2008
A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Journal of cardiac failure, 2011, Volume: 17, Issue:12

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure, Systolic; Humans; Male; Middle Aged; Statistics as Topic; Stroke Volume; Tolvaptan; Vasopressins; Ventricular Function, Left

2011
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Circulation. Heart failure, 2012, Volume: 5, Issue:6

    Topics: Aged; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Lymphocyte Count; Male; Middle Aged; Predictive Value of Tests; Prognosis; Regression Analysis; Stroke Volume; Tolvaptan; Vasopressins

2012
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
    Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5

    Topics: Aged; Aged, 80 and over; Benzazepines; Clinical Protocols; Double-Blind Method; Europe; Europe, Eastern; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Internationality; Male; Middle Aged; North America; Patient Selection; Prospective Studies; South America; Survival Rate; Tolvaptan; Treatment Outcome; Vasopressins

2013
Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2014, Aug-15, Volume: 307, Issue:4

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Deamino Arginine Vasopressin; Double-Blind Method; Exercise; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neurophysins; Osmolar Concentration; Physical Endurance; Plasma Volume; Protein Precursors; Receptors, Vasopressin; Running; Signal Transduction; Sodium; Sweat; Sweat Glands; Sweating; Thirst; Time Factors; Tolvaptan; Vasopressins; Water-Electrolyte Balance; Weight Loss; Young Adult

2014
Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
    BMC nephrology, 2014, Jun-25, Volume: 15

    Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Body Water; Brachial Artery; Cross-Over Studies; Double-Blind Method; Female; Humans; Kidney; Male; Nitric Oxide; omega-N-Methylarginine; Placebo Effect; Reference Values; Sodium; Tolvaptan; Vasopressins; Young Adult

2014
Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Endocrine journal, 2021, Jan-28, Volume: 68, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Japan; Male; Middle Aged; Tolvaptan; Treatment Outcome; Vasopressins; Young Adult

2021

Other Studies

29 other study(ies) available for tolvaptan and pituitrin

ArticleYear
Aminocarbonylation route to tolvaptan.
    Bioorganic & medicinal chemistry letters, 2007, Dec-01, Volume: 17, Issue:23

    Topics: Benzazepines; Catalysis; Chemistry, Pharmaceutical; Palladium; Tolvaptan; Vasopressins

2007
Introduction: Vasopressin therapy.
    Heart failure reviews, 2009, Volume: 14, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan; Vasopressins

2009
The vaptans ante portas: a status report.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:5

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Tolvaptan; Treatment Outcome; Vasopressins

2009
Hyponatremia: vasopressin antagonists in hyponatremia: more data needed.
    Nature reviews. Nephrology, 2011, Volume: 7, Issue:3

    Topics: Benzazepines; Clinical Trials as Topic; Drug Resistance; Humans; Hyponatremia; Tolvaptan; Vasopressins

2011
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.
    American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:5

    Topics: Adult; Aged; Amiloride; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blotting, Western; Cell Proliferation; Cells, Cultured; Chlorides; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Diuretics; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Agents; Tolvaptan; Vasopressins

2011
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    The Journal of biological chemistry, 2012, Jan-13, Volume: 287, Issue:3

    Topics: Amino Acid Substitution; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Membrane; Child; Child, Preschool; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Humans; Male; Mutation, Missense; Neurophysins; Protein Precursors; Receptors, Vasopressin; Tolvaptan; Vasopressins

2012
Antidiuretic hormone antagonist to reduce cystine stone formation.
    Annals of internal medicine, 2012, Sep-18, Volume: 157, Issue:6

    Topics: Adult; Benzazepines; Cystinuria; Female; Humans; Kidney Calculi; Male; Middle Aged; Secondary Prevention; Tolvaptan; Vasopressins

2012
Are all clinical trial sites created equal?
    Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5

    Topics: Benzazepines; Female; Heart Failure; Humans; Male; Patient Selection; Tolvaptan; Vasopressins

2013
Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2013, May-15, Volume: 304, Issue:10

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Brain; Gene Expression; Hypertension; Hypothalamus; Mice; Mice, Transgenic; Receptors, Vasopressin; Renin-Angiotensin System; Tolvaptan; Vasopressins

2013
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs.
    Hearing research, 2016, Volume: 332

    Topics: Administration, Oral; Administration, Topical; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Endolymphatic Hydrops; Endolymphatic Sac; Female; Guinea Pigs; Meniere Disease; Osmolar Concentration; Receptors, Vasopressin; Tolvaptan; Vasopressins; Water-Electrolyte Balance

2016
Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites.
    World journal of gastroenterology, 2016, Mar-28, Volume: 22, Issue:12

    Topics: Animals; Aquaporin 2; Ascites; Benzazepines; Carbon Tetrachloride; Colon; Diarrhea; Dose-Response Relationship, Drug; Feces; Liver Cirrhosis, Experimental; Male; Rats, Sprague-Dawley; Sodium; Time Factors; Tolvaptan; Vasopressins; Water

2016
Predictors for Tolvaptan Treatment and Future Perspectives.
    International heart journal, 2016, Jul-27, Volume: 57, Issue:4

    Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Arginine; Benzazepines; Biomarkers; Diuresis; Dose-Response Relationship, Drug; Evidence-Based Medicine; Heart Failure; Humans; Predictive Value of Tests; Prognosis; Renin-Angiotensin System; Sensitivity and Specificity; Severity of Illness Index; Tolvaptan; Treatment Outcome; Vasopressins

2016
[Current options of treatment of hyponatremia].
    Vnitrni lekarstvi, 2016,Winter, Volume: 62 Suppl 6

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Europe; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan; Vasopressins

2016
Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:2

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Resistance; Fatal Outcome; Female; Genetic Diseases, X-Linked; Humans; Inappropriate ADH Syndrome; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Sodium; Tolvaptan; Vasopressins

2018
A diuretic-sparing strategy to facilitate deactivation of vasopressin secretion.
    Journal of internal medicine, 2018, Volume: 283, Issue:4

    Topics: Acute Kidney Injury; Animals; Diuretics; Heart Failure; Humans; Rats, Wistar; Tolvaptan; Vasopressins

2018
Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, Volume: 71, Issue:6

    Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Hyponatremia; Inappropriate ADH Syndrome; Tolvaptan; Vasopressins

2018
Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2019, Volume: 41, Issue:4

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Blood Pressure; Hypertension; Kidney Medulla; Male; Methylamines; Osmolar Concentration; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tolvaptan; Vasopressins

2019
Sensory primary cilium is a responsive cAMP microdomain in renal epithelia.
    Scientific reports, 2019, 04-25, Volume: 9, Issue:1

    Topics: Adenylyl Cyclases; Animals; Calcium; Cell Line; Cilia; Colforsin; Cyclic AMP; Cytosol; Dogs; Epithelial Cells; Gene Knockdown Techniques; Isoenzymes; Membrane Microdomains; Mice; Receptors, Vasopressin; Signal Transduction; Stress, Mechanical; Swine; Tolvaptan; Vasopressins

2019
Syndrome of inappropriate antidiuretic hormone release as the initial presentation of adenocarcinoma of the colon.
    The journal of the Royal College of Physicians of Edinburgh, 2020, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Colon; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Tolvaptan; Vasopressins

2020
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Scientific reports, 2020, 10-02, Volume: 10, Issue:1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Line; Cell Membrane; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Dogs; Endoplasmic Reticulum; Humans; Madin Darby Canine Kidney Cells; Male; Mutation; Protein Transport; Receptors, Vasopressin; Tolvaptan; Vasopressins

2020
Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Advances in therapy, 2021, Volume: 38, Issue:2

    Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Germany; Humans; Hyponatremia; Inappropriate ADH Syndrome; Retrospective Studies; Spain; Tolvaptan; Vasopressins

2021
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
    International heart journal, 2021, Sep-30, Volume: 62, Issue:5

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Biomarkers; Body Fluids; Cardiac Surgical Procedures; Female; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Postoperative Care; Prospective Studies; Tolvaptan; Vasopressins

2021
[A case of SIADH due to pancreatic cancer was improved by tolvaptan].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2022, Volume: 119, Issue:2

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Inappropriate ADH Syndrome; Male; Pancreatic Neoplasms; Quality of Life; Tolvaptan; Vasopressins

2022
[Tolvaptan, a vasopressin V
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2022, Volume: 157, Issue:4

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cyclic AMP; Cysts; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins

2022
Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
    International heart journal, 2023, Mar-31, Volume: 64, Issue:1

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins

2023
Structure-Affinity and Structure-Kinetic Relationship Studies of Benzodiazepine Derivatives for the Development of Efficacious Vasopressin V
    Journal of medicinal chemistry, 2023, 03-09, Volume: 66, Issue:5

    Topics: Anti-Anxiety Agents; Anticonvulsants; Antidiuretic Hormone Receptor Antagonists; Benzodiazepines; Humans; Hypnotics and Sedatives; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Vasopressins

2023
Syndrome of inappropriate secretion of anti-diuretic hormone due to hypothalamic hamartoma: use of tolvaptan.
    Journal of pediatric endocrinology & metabolism : JPEM, 2023, Sep-26, Volume: 36, Issue:9

    Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Humans; Hyponatremia; Inappropriate ADH Syndrome; Seizures; Tolvaptan; Vasopressins

2023
Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2023, Volume: 131, Issue:9

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Pituitary Gland, Posterior; Tolvaptan; Vasopressins

2023
Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    The Journal of veterinary medical science, 2023, Oct-17, Volume: 85, Issue:10

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dog Diseases; Dogs; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Sodium; Tolvaptan; Vasopressins

2023